Up next

2026: Drugs To Watch: The Year Ahead

Matthew Arnold, Principal Analyst and Content Strategist, Clarivate

Which bio/pharmaceuticals, slated to be launched or approved in 2026, may be potential blockbusters or are raising the innovation bar to new heights? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, highlights the 11 drugs making Clarivate’s Drugs to Watch list in 2026, key trends in product innovation, and the companies and products on the industry’s radar.

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights, or get each episode through: 

For a full list of the 2026 podcast episode schedule, click here.

You May Also Like

2025: The Bio/Pharma Industry’s Year in Review

By
Without question, evolving US tariff and trade policy was the story of the year, and how such policy will be implemented looms large. At the same time, the normal course…

What’s Trending: ADCs: Pipelines, Products & CDMO Growth 

By
Sponsored by Lonza AG Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are…

Drug Launches & Approvals in 2025: The Blockbuster Contenders

By
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal…

CDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?

By
Sponsored by Vetter Pharma International GmbH What will be the impact of US tariffs on CDMOs of injectables and on the decision-making of pharma companies on in-sourced/outsourced activity overall and…